Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NAIM ALKHOURI

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1134336662
CMS profile
277931
Location
WESTLAKE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$84,282.13

118 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NAIM ALKHOURI

NPI 1134336662 · CMS profile ID 277931

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

WESTLAKE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NAIM ALKHOURI, NPI 1134336662, CMS profile ID 277931. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NAIM ALKHOURI, NPI 1134336662, CMS profile ID 277931. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NAIM ALKHOURI, NPI 1134336662, CMS profile ID 277931, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

118 matching records · $84,282.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 118 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 118.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $3,000.0007/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845851807 CMS
Gilead Sciences, Inc. $100.2707/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154559 CMS
Gilead Sciences, Inc. $18.8807/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154557 CMS
Boehringer Ingelheim International GmbH $600.0007/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 822296785 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.5807/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850168607 CMS
Eisai Inc. $21.6307/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818057019 CMS
Gilead Sciences, Inc. $3.8707/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154555 CMS
AbbVie Inc. $27.6207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793854585 CMS
Eisai Inc. $23.5506/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833776829 CMS
Gilead Sciences, Inc. $1,350.0006/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845851805 CMS
Gilead Sciences, Inc. $10.4606/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154553 CMS
Alexion Pharmaceuticals, Inc. $1,000.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783109419 CMS
Gilead Sciences, Inc. $16.6806/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154551 CMS
Theratechnologies Inc. $3,000.0006/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834896465 CMS
AbbVie Inc. $28.0406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793854581 CMS
Alexion Pharmaceuticals, Inc. $1,000.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783109421 CMS
Intercept Pharmaceuticals, Inc. $570.0006/15/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836203105 CMS
Gilead Sciences, Inc. $3.3806/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154549 CMS
Gilead Sciences, Inc. $3.3506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154547 CMS
Merck Sharp & Dohme Corporation $17.1906/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848431029 CMS
Novo Nordisk Inc $2,160.0006/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849783117 CMS
AbbVie Inc. $40.0406/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793854577 CMS
Gilead Sciences, Inc. $95.8106/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154545 CMS
Intercept Pharmaceuticals, Inc. $570.0006/01/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836203103 CMS
Novo Nordisk Inc $1,080.0006/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849786921 CMS
Gilead Sciences, Inc. $3.8005/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154543 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.5005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850029211 CMS
Intercept Pharmaceuticals, Inc. $114.4805/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836203099 CMS
Intercept Pharmaceuticals, Inc. $3,400.0005/13/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836203101 CMS
AbbVie Inc. $22.5805/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793854573 CMS
Gilead Sciences, Inc. $3.5305/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154541 CMS
Gilead Sciences, Inc. $3.2705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154539 CMS
Gilead Sciences, Inc. $5.8404/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154537 CMS
Novo Nordisk Inc $32.2704/30/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849783113 CMS
Novo Nordisk Inc $32.2704/30/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849797893 CMS
Novo Nordisk Inc $32.2704/30/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849797895 CMS
Novo Nordisk Inc $32.2704/30/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849797897 CMS
Gilead Sciences, Inc. $2.9304/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154535 CMS
Gilead Sciences, Inc. $2.7504/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154533 CMS
Eisai Inc. $36.6804/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833770647 CMS
Gilead Sciences, Inc. $19.8904/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154531 CMS
Gilead Sciences, Inc. $13.0504/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154529 CMS
Eisai Inc. $30.0104/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818056419 CMS
Alexion Pharmaceuticals, Inc. $1,000.0004/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783109347 CMS
PFIZER INC. $1,600.0004/01/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833388247 CMS
Gilead Sciences, Inc. $3.6403/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848154527 CMS
Intercept Pharmaceuticals, Inc. $520.0003/25/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836203097 CMS
AbbVie Inc. $29.0303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793854569 CMS
Eisai Inc. $1,470.0003/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833763915 CMS
Gilead Sciences, Inc. $400.0003/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845851803 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $230,526.84 227
PY2020 $69,134.33 64
PY2021 $84,282.13 118
PY2022 $249,012.90 165
PY2023 $308,692.39 166
PY2024 $373,812.08 240
PY2025 $606,750.42 344

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $35,289.77 37
PY2025 Principal investigator $890,501.10 106
PY2024 Recipient $7,857.76 13
PY2024 Principal investigator $2,051,472.57 233
PY2023 Principal investigator $2,475,441.45 155
PY2022 Recipient $4,281.01 6
PY2022 Principal investigator $247,137.49 39
PY2021 Recipient $16,730.00 14
PY2021 Principal investigator $424,276.54 231
PY2020 Recipient $330.00 1
PY2020 Principal investigator $736,691.04 49
PY2019 Recipient $1,496.76 7
PY2019 Principal investigator $1,383,155.00 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

143 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Eli Lilly and Company $915.38 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187872851
Recipient Eli Lilly and Company $934.02 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187876949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,160.00 11/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223288109
Principal investigator 1 Grifols Shared Services North America, Inc. $140.00 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167561
Principal investigator 1 Grifols Shared Services North America, Inc. $56.00 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167563
Principal investigator 1 Grifols Shared Services North America, Inc. $77.00 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167565
Principal investigator 1 Grifols Shared Services North America, Inc. $105.00 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167567
Principal investigator 1 Grifols Shared Services North America, Inc. $110.60 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167569
Principal investigator 1 Grifols Shared Services North America, Inc. $121.80 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167571
Principal investigator 1 Grifols Shared Services North America, Inc. $175.00 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167573
Principal investigator 1 Grifols Shared Services North America, Inc. $280.00 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167575
Principal investigator 1 Grifols Shared Services North America, Inc. $420.00 10/08/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $758.70 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,150.00 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.00 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,064.50 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244517
Principal investigator 1 Gilead Sciences, Inc. $17,450.00 10/01/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206979
Principal investigator 1 Grifols Shared Services North America, Inc. $1,242.25 09/11/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167529
Principal investigator 1 AstraZeneca UK Limited $36,721.00 08/06/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH II LLC
A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA No dispute reported 06/30/2026 1185542764
Principal investigator 1 Grifols Shared Services North America, Inc. $1,000.00 06/27/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167553
Principal investigator 1 Grifols Shared Services North America, Inc. $2,000.00 06/27/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167555
Principal investigator 1 Grifols Shared Services North America, Inc. $2,500.00 06/27/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167557
Principal investigator 1 Grifols Shared Services North America, Inc. $15,000.00 06/27/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167559
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685075
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685077
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 06/24/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685079
Principal investigator 1 Madrigal Pharmaceuticals $2,353.39 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245380
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 06/11/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192127894
Principal investigator 1 GlaxoSmithKline, LLC. $850.00 06/11/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192127907
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/11/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192127914
Principal investigator 1 GlaxoSmithKline, LLC. $850.00 06/11/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192127921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,835.68 06/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.00 06/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204465
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,248.60 06/04/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA No dispute reported 06/30/2026 1185542770
Principal investigator 1 GlaxoSmithKline, LLC. $16,977.45 05/26/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123689
Principal investigator 1 Madrigal Pharmaceuticals $2,609.89 05/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244276
Recipient Boehringer Ingelheim International GmbH $627.00 05/16/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623718
Recipient Boehringer Ingelheim International GmbH $18.00 05/16/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623728
Recipient Boehringer Ingelheim International GmbH $60.00 05/16/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623730
Recipient Boehringer Ingelheim International GmbH $11.62 05/16/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623732
Recipient Boehringer Ingelheim International GmbH $47.00 05/15/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623722
Recipient Boehringer Ingelheim International GmbH $17.00 05/15/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623724
Recipient Boehringer Ingelheim International GmbH $77.25 05/15/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623726
Recipient Boehringer Ingelheim International GmbH $7,040.20 05/15/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623734
Recipient Boehringer Ingelheim International GmbH $71.86 05/15/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623736
Principal investigator 1 Madrigal Pharmaceuticals $12,780.13 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243781
Recipient Boehringer Ingelheim International GmbH $80.00 05/14/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623720
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685073
Principal investigator 1 Eli Lilly and Company $20,000.00 04/30/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH LLC
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1187881824
Principal investigator 1 Ipsen Bioscience Inc. $9,431.03 04/23/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,709.25 04/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184188965
Principal investigator 1 Gilead Sciences, Inc. $6,604.00 04/22/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206973
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242044
Principal investigator 1 Madrigal Pharmaceuticals $50.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242097
Principal investigator 1 Madrigal Pharmaceuticals $1,662.50 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242101
Principal investigator 1 GlaxoSmithKline, LLC. $4,936.96 04/09/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123683
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685065
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685067
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 04/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685069
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 04/01/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,139.50 04/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184180608
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123664
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123670
Principal investigator 1 GlaxoSmithKline, LLC. $560.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123677
Principal investigator 1 GlaxoSmithKline, LLC. $42.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123696
Principal investigator 1 GlaxoSmithKline, LLC. $420.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123702
Principal investigator 1 GlaxoSmithKline, LLC. $176.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123714
Principal investigator 1 GlaxoSmithKline, LLC. $280.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127875
Principal investigator 1 GlaxoSmithKline, LLC. $490.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127880
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127900
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127925
Principal investigator 1 GlaxoSmithKline, LLC. $88.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129867
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192179306
Principal investigator 1 GlaxoSmithKline, LLC. $42.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192179310
Principal investigator 1 GlaxoSmithKline, LLC. $88.00 03/31/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192179314
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685055
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685057
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685059
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685061
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685063
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
-Ph III MASH pivotal trial (MASH F4) No dispute reported 06/30/2026 1220685081
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
-Ph III MASH pivotal trial (MASH F4) No dispute reported 06/30/2026 1220685083
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
-Ph III MASH pivotal trial (MASH F4) No dispute reported 06/30/2026 1220685085
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
-Ph III MASH pivotal trial (MASH F4) No dispute reported 06/30/2026 1220685087
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
-Ph III MASH pivotal trial (MASH F4) No dispute reported 06/30/2026 1220685089
Principal investigator 1 Grifols Shared Services North America, Inc. $3,425.00 03/25/2025 Non-covered Recipient Entity
The Institute of Liver Health II LLC dba Arizona Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167597
Principal investigator 1 GlaxoSmithKline, LLC. $12,648.30 03/21/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,569.75 03/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184174314
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685039
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685041
Principal investigator 1 Boehringer Ingelheim International GmbH $259.00 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685043
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685045
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685047
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685049
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685051
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 03/14/2025 Non-covered Recipient Entity
The Institute for Liver Health II LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220685053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,139.50 03/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184170716
Principal investigator 1 Madrigal Pharmaceuticals $12,621.08 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240244
Principal investigator 1 Ipsen Bioscience Inc. $6,386.80 03/04/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 03/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,000.00 03/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,200.00 03/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,066.00 03/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156552
Principal investigator 1 Madrigal Pharmaceuticals $12,015.00 02/27/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240003
Principal investigator 1 GlaxoSmithKline, LLC. $4,297.23 02/24/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123708
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,659.55 02/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223275497
Recipient Boehringer Ingelheim International GmbH $7.95 02/23/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623770
Recipient Boehringer Ingelheim International GmbH $41.10 02/23/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623772
Recipient Boehringer Ingelheim International GmbH $8.46 02/23/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623774
Recipient Boehringer Ingelheim International GmbH $41.10 02/23/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623776
Recipient Boehringer Ingelheim International GmbH $8.46 02/23/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623778
Recipient Boehringer Ingelheim International GmbH $41.10 02/23/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623780
Recipient Boehringer Ingelheim International GmbH $8.46 02/23/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623782
Recipient PFIZER INC. $1,400.00 02/22/2025 Covered Recipient Physician PF06835919 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228829613
Principal investigator 1 AstraZeneca UK Limited $210,950.90 02/21/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA No dispute reported 06/30/2026 1185542766
Recipient Boehringer Ingelheim International GmbH $62.00 02/21/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623784
Principal investigator 1 Eli Lilly and Company $13,900.00 02/20/2025 Non-covered Recipient Entity
ARIZONA RESEARCH CENTER
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1187874643
Recipient Boehringer Ingelheim International GmbH $1,050.76 02/14/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623738
Recipient Boehringer Ingelheim International GmbH $87.64 02/14/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623740
Recipient Boehringer Ingelheim International GmbH $98.59 02/14/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623742
Recipient Boehringer Ingelheim International GmbH $7,415.41 02/12/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623744
Recipient Boehringer Ingelheim International GmbH $131.45 02/12/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623746
Principal investigator 1 Madrigal Pharmaceuticals $9,394.31 02/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239081
Recipient Boehringer Ingelheim International GmbH $471.21 01/31/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623748
Recipient Boehringer Ingelheim International GmbH $15.39 01/31/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623758
Recipient Boehringer Ingelheim International GmbH $47.01 01/31/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623760
Recipient Boehringer Ingelheim International GmbH $15.39 01/31/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623762
Recipient Boehringer Ingelheim International GmbH $47.01 01/30/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623752
Recipient Boehringer Ingelheim International GmbH $15.39 01/30/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623754
Recipient Boehringer Ingelheim International GmbH $51.31 01/30/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623756
Recipient Boehringer Ingelheim International GmbH $71.84 01/29/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623750
Recipient Boehringer Ingelheim International GmbH $14,155.63 01/29/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623764
Recipient Boehringer Ingelheim International GmbH $48.45 01/29/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623766
Recipient Boehringer Ingelheim International GmbH $49.33 01/29/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220623768
Principal investigator 1 Ipsen Bioscience Inc. $6,431.60 01/29/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545569
Principal investigator 1 GlaxoSmithKline, LLC. $17,473.54 01/28/2025 Non-covered Recipient Entity
INSTITUTE FOR LIVER HEALTH
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127888
Principal investigator 1 Madrigal Pharmaceuticals $3,537.50 01/23/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,139.50 01/21/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149196
Principal investigator 1 Madrigal Pharmaceuticals $2,867.67 01/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238378
Principal investigator 1 AstraZeneca Pharmaceuticals LP $268,873.56 01/08/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele No dispute reported 06/30/2026 1185542768
Principal investigator 1 Ipsen Bioscience Inc. $280.00 01/07/2025 Non-covered Recipient Entity
Arizona Liver Health
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545567
Principal investigator 1 Madrigal Pharmaceuticals $1,823.71 01/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238067
Principal investigator 1 Madrigal Pharmaceuticals $3,009.69 01/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237923